Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of the Probiotic Preparation VSL#3 on the Metabolic, Endocrine, Lipidomic and Inflammatory Parameters as Well as Variation of the Microbiota in Pediatric Patients With Body Mass Index >90°
Brief Summary: Obesity in children has become a significant social problem considering that nowadays 4 to 5 % of all children are obese in the industrialized countries with increased incidence in Europe by 10 to 50% over the past 10 years. Obesity is associated with the metabolic syndrome in 30% of the children and is considered as a state of chronic inflammation inducing the production of pro-inflammatory cytokines which determine metabolic and endocrine alterations on the organism. It has been observed that obesity is also linked to a change in the intestinal microflora with a reduction of Bacterioides and bifidobacteria and a decrease of Firmicutes and Staphylococcus aureus. The qualitative and quantitative analysis of the metabolites may provide us with a characterization of the existing phenotypes and variations in relation to the changes of the physiological state, in particular when supplemented or not with a probiotic preparation.


Options:
A: Arm Label: Rifaximin; Type: EXPERIMENTAL; Interventions: Drug: Rifaximin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rifaximin; Assigned to Arm(s): Rifaximin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: VSL#3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: VSL#3 placebo | Arm Label: VSL#3 active probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 active probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 active probiotic; Assigned to Arm(s): VSL#3 active probiotic | Intervention Type: OTHER; Name: VSL#3 placebo; Assigned to Arm(s): VSL#3 placebo
C: Arm Label: Neomycin prescribed; Type: EXPERIMENTAL; Interventions: Drug: Neomycin | Arm Label: Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed; Type: EXPERIMENTAL; Interventions: Drug: Lactobacillus casei rhamnosus (Lcr35) | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Lactobacillus casei rhamnosus (Lcr35); Assigned to Arm(s): Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed | Intervention Type: DRUG; Name: Neomycin; Assigned to Arm(s): Neomycin prescribed
D: Arm Label: Optimal Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimal Diet | Arm Label: VSL#3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: VSL#3® | Arm Label: AISA-5203-L; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AISA-5203-L | Arm Label: Argan oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Argan oil | Intervention Type: BEHAVIORAL; Name: Optimal Diet; Assigned to Arm(s): Optimal Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3®; Assigned to Arm(s): VSL#3 | Intervention Type: DIETARY_SUPPLEMENT; Name: AISA-5203-L; Assigned to Arm(s): AISA-5203-L | Intervention Type: DIETARY_SUPPLEMENT; Name: Argan oil; Assigned to Arm(s): Argan oil

Answer: B